Insmed Incorporated (NASDAQ:INSM) Stock Holdings Boosted by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. boosted its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 237.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 59,600 shares of the biopharmaceutical company's stock after buying an additional 41,918 shares during the quarter. Harbor Capital Advisors Inc.'s holdings in Insmed were worth $4,115,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the stock. V Square Quantitative Management LLC purchased a new stake in shares of Insmed in the third quarter valued at $30,000. GAMMA Investing LLC lifted its holdings in Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 224 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company's stock worth $55,000 after purchasing an additional 627 shares during the last quarter. JCIC Asset Management Inc. purchased a new stake in shares of Insmed during the third quarter worth about $133,000. Finally, Quantbot Technologies LP acquired a new position in shares of Insmed in the third quarter valued at approximately $133,000.

Insmed Stock Down 0.7 %

NASDAQ:INSM traded down $0.47 during trading hours on Friday, hitting $65.25. The stock had a trading volume of 3,087,759 shares, compared to its average volume of 1,881,810. The business has a 50 day simple moving average of $71.23 and a two-hundred day simple moving average of $72.44. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $80.53. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market cap of $11.67 billion, a PE ratio of -11.76 and a beta of 1.12.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to analysts' expectations of $93.36 million. Insmed's revenue for the quarter was up 18.1% compared to the same quarter last year. During the same quarter last year, the business earned ($1.10) earnings per share. Analysts predict that Insmed Incorporated will post -5.44 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on INSM. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 target price on shares of Insmed in a research note on Friday, November 1st. Bank of America increased their target price on Insmed from $84.00 to $86.00 and gave the stock a "buy" rating in a research report on Wednesday, October 9th. JPMorgan Chase & Co. lifted their price target on Insmed from $74.00 to $83.00 and gave the company an "overweight" rating in a report on Friday, November 22nd. Finally, Truist Financial reiterated a "buy" rating and set a $105.00 price objective (up from $100.00) on shares of Insmed in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, Insmed has a consensus rating of "Moderate Buy" and a consensus price target of $83.67.

Insider Activity at Insmed

In other news, COO Roger Adsett sold 2,444 shares of the firm's stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $65.95, for a total value of $161,181.80. Following the transaction, the chief operating officer now directly owns 147,666 shares in the company, valued at approximately $9,738,572.70. This trade represents a 1.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $69.91, for a total transaction of $1,310,812.50. Following the sale, the chief executive officer now owns 384,960 shares in the company, valued at approximately $26,912,553.60. This trade represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 70,094 shares of company stock valued at $4,733,986. Insiders own 4.60% of the company's stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.